Executive Director, Head of Automation and Assay Technologies
Bristol Myers Squibb, New Jersey, United States
Andrew Napper, Ph.D., is currently Executive Director, Head of Automation and Assay Technologies at Bristol Myers Squibb in Princeton, NJ. He is a native of England. After a BA and MA in Chemistry from the University of Oxford, he moved to the USA for a Ph.D. in Chemistry focused on enzymology in the lab of Steve Benkovic at Penn State University. Andrew moved directly from his Ph.D. to Igen, Inc., an early-stage biotech company in Maryland. After two years he moved to Boston/Cambridge where he spent 14 years at Genzyme and various smaller biotech companies. In 2005 he joined the University of Pennsylvania to direct a new high-throughput screening lab in the NIH Molecular Libraries Screening Center Network, and in 2009 continued in academic/non-profit drug discovery for a further 8 years at the Nemours/A.I. duPont Hospital for Children in Wilmington, DE. After one year at FLX Bio in the San Francisco Bay Area, Andrew moved to Princeton NJ in 2018 to join Evotec as Vice President Discovery Sciences at Evotec and Princeton Site Head. He joined Bristol Myers Squibb in March 2021 and currently leads Compound Management, Core Automation, Data Analytics, High-content Imaging, and Lead Discovery Informatics teams in Princeton and across the US east and west coasts.
Disclosure information not submitted.
Wednesday, February 9, 2022
9:00 AM – 10:00 AM